Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus

NCT07483359 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)
Portal Vein Tumor Thrombus

Interventions

COMBINATION_PRODUCT: HAIC + Tislelizumab +lenvatinib

Sponsor

First Hospital of China Medical University

Collaborators

[object Object]
[object Object]